Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vobarilizumab Open-Label Extension in Rheumatoid Arthritis
NCT02518620Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jul 2015
- Primary completion
- Aug 2018
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 2, open-label, single-arm trial of vobarilizumab in rheumatoid arthritis (RA), sponsored by Sanofi. Primary endpoints: American College of Rheumatology 20% Response at 104 weeks, American College of Rheumatology 50% Response at 104 weeks and 4 more. Started Jul 2015; status: completed.
02
Drugs
vobarilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02518620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02518620.